Blog
With the FDA ending the two-trial default, the era of intelligent evidence has begun
Truveta Live Link: Enabling more complete real-world evidence and prospective research
Truveta experts: Antidepressant treatment duration trends
Real-world evidence on heart failure from GLP-1 and advanced CKD populations
Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity
Hematologic oncology at scale: From population insight to patient-level risk signals
Truveta experts: What adolescent sleep disorders reveal about mental health trends
